In addition, certain infectious models like malaria seem to benefit from MyD88-dependent signalling and inflammation in their pathology, and thus a completely different approach should be used when trying to fight Plasmodium. As opposed to using TLR ligands which can worsen the disease, TLR agonists could prove clinically effective in treating malaria. This evidence concerns the gene MYD88 and malaria.